Skip to main content
Advanced Technical IVT

synthetic lethality

A therapeutic strategy where combined inhibition of two genes or pathways is lethal to cancer cells but tolerable to normal cells.

Full Definition

Synthetic lethality is a genetic interaction where the simultaneous disruption of two genes or pathways results in cell death, while disruption of either alone is survivable. In precision oncology, this concept is exploited therapeutically by targeting pathways that are essential for survival in cancer cells with specific genetic defects but dispensable in normal cells. The classic example involves PARP inhibitors in BRCA-deficient cancers, where cancer cells cannot repair DNA damage through either pathway. This approach expands the druggable genome beyond traditional oncogenes and tumor suppressors, creating therapeutic opportunities for cancers with loss-of-function mutations that are typically considered undruggable.

Usage

Usage note: Always provide mechanistic context when first introduced in clinical documents

In Context

  • "PARP inhibitors exploit synthetic lethality in BRCA-mutated ovarian cancers." — Mechanism of action documentation
  • "Identifying synthetic lethal partners of tumor suppressors represents a major therapeutic opportunity." — Drug discovery research proposal

Also known as

synthetic lethal interaction

Contrasted with

synthetic rescue

Don't confuse with

oncogene addiction tumor suppressor loss essential gene dependency

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON